Log In
Print
BCIQ
Print
Print this Print this
 

Brimica Genuair, Duaklir Genuair, Aclidinium bromide/formoterol fumarate (KRP-AB1102F, LAS40464)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionFixed-dose combination of aclidinium bromide with the long acting beta agonist (LABA) formoterol
Molecular Target Adrenergic receptor beta 2 (ADRB2) ; Muscarinic receptor
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation EU - Standard Review (Treat chronic obstructive pulmonary disease (COPD))
Partner Allergan plc; Kyorin Pharmaceutical Co. Ltd.; Menarini Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$2,795.0M

$1,575.0M

$1,220.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today